



(51) International Patent Classification:

A61K 31/593 (2006.01) *A61P 3/08* (2006.01)
A61P 3/02 (2006.01) *A61P 13/08* (2006.01)
A61P 19/10 (2006.01) *A61P 35/00* (2006.01)
A61P 17/06 (2006.01) *A61P 5/18* (2006.01)

(21) International Application Number:

PCT/EP2010/056832

(22) International Filing Date:

18 May 2010 (18.05.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/179,906 20 May 2009 (20.05.2009) US

(71) Applicant (for all designated States except US): **HYBRI-GENICS SA** [FR/FR]; 3/5 Impasse Reille, F-75014 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DELANSORNE, Rémi** [FR/FR]; 30, rue Guynemer, F-75006 Paris (FR). **DUFOUR-LAMARTINIE, Jean-François** [FR/FR]; 132, rue de la Roquette, F-75011 Paris (FR).

(74) Agents: **JACOBSON, Claude** et al.; Cabinet LAVOIX, 2 Place d'Estienne d'Orves, F-75441 Paris Cedex 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NEW THERAPEUTICAL USES OF INECALCITOL

(57) Abstract: The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof.

